OS in MCL (excluding patients who had undergone ASCT as first-line therapy). (Top left) Median OS for MCL with an indolent clinical course (n = 16, defined as not requiring treatment within the first 2 years after diagnosis) and nonindolent MCL (n = 130) were 2168 days (5.9 years) and 1031 days (2.8 years), respectively (P = .004). (Top right) Median LSS for nonindolent MCL was 1133 days (3.1 years) and was not reached for indolent MCL. (Bottom left) Median OS for non-ASCT treated SOX11⁺ (n = 129) and SOX11⁻ (n = 12) cases were 1180 days (3.2 years) and 494 days (1.5 years), respectively (P = .014). (Bottom right) Median OS for non-ASCT treated p53⁻ cases (n = 104) and p53⁺ (n = 33) cases were 1391 days (3.8 years) and 477 days (1.3 years), respectively (P < .001).